---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-294696"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:30:18.248559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers

## Summary
- Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.
- Licensed field of use: prostate cancer, basal cell carcinoma (including BCC nevus syndrome), and lung cancer.
- Financial terms include upfront fee, minimum annual royalties, milestone payments, and royalties on net sales.
- Company cites this as a critical milestone toward commercializing itraconazole in multiple oncology indications.

## SEC filing metadata
- accession: 0001193125-23-294696
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/0001193125-23-294696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/d502337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-294696
- JSON: https://secwatch.observer/filing/0001193125-23-294696.json
- Plain text: https://secwatch.observer/filing/0001193125-23-294696.txt

## Key facts
- Material Agreements
  Inhibitor Therapeutics, Inc. entered into Exclusive License Agreement with Johns Hopkins University valued at License agreement including upfront license fee, minimum annual royalty payments, royalties on net s (effective 2023-12-12).
  - Action: entry
  - Agreement: license
  - Counterparty: Johns Hopkins University
  - Value: License agreement including upfront license fee, minimum annual royalty payments, royalties on net s
  - Effective: 2023-12-12
  source text: On December 12, 2023, Inhibitor Therapeutics, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University (“JHU”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/0001193125-23-294696-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.